I expect to see an increase in Fusilev sales of 5-8% on a quarterly
basis for some time. It´s the only drug approved to be used with FU.
You never have peak sales for a drug that´s appoved for colorectal
cancer for such a short time. With possible new indications for our 2
approved drugs and 2 NDA´s in 2012 the market will recognize Spectrum soon. The growth should be rewarded with a p/e
expansion over time.
I find no Biotech stock that is so undervalued while
having 2 drugs approved and 2 near NDA. The cash position and the share
buy back add to my bullishness.
QCOR is a nice example what happens when the market realizes the full potential of a company. 1 drug, but 19 indications. Look at the chart. I wouldn´t be suprised to see a similar move of SPPI especially with new indications and a possible new approval.